• Citer

The impact of anti-craving medication on cue reactivity and abstinence in patients undergoing alcohol detoxification: some preliminary evidence from a retrospective event-related potentials study

par Dousset, Clémence ;Sistiaga, Sonia ;Ingels, Anais ;Hanak, Catherine ;Kajosch, Hendrik ;Campanella, Salvatore
Référence Psychopharmacology, page (1-13)
Publication Publié, 2025-06-27

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Rationale While medications such as acamprosate, baclofen, or naltrexone have shown promising effects in the treatmentof alcohol use disorder (AUD), meta-analyses have yielded conflicting findings regarding their efficacy. This retrospectivestudy examined whether alcohol cue reactivity and its neural correlates could serve as protective factors against relapse inAUD inpatients receiving pharmacological treatment during a three-week detoxification program.Method Fifty-eight inpatients diagnosed with AUD undergoing a three-weeks detoxification program were selected. Thesepatients received either acamprosate (n=21), naltrexone (n=21), or baclofen (n=16) during their stay. They completed anevent-related potential cue-reactivity task at the beginning (T0) and end (T1) of the program. Follow-up data on relapse werecollected up to two months post- discharge. Results The Log-Rank (Mantel-Cox) test (χ2(2)=5.84; p =.059) revealed a marginally significant difference in survival distributions between medications. A significant difference emerged between baclofen and acamprosate groups (χ2(1)=4.73;p =.030), with slower return to alcohol use in the baclofen group. No other significant difference emerged between the acam-prosate and naltrexone groups or between the naltrexone and baclofen groups (p >.05). Only the baclofen group showed asignificant reduction in oddball P3 amplitude between T0 and T1 (p =.002), suggesting decreased neural cue reactivity.Conclusion A reduction in neural cue reactivity, observed exclusively in the baclofen group, may act as a protective factoragainst early relapse in AUD. However, this study was underpowered, and findings should be interpreted cautiously untilconfirmed in larger prospective investigations.